Cancer is a major chronic disease, which can be managed and treated by chemotherapy, radiation therapy, immunotherapy, hormone therapy, stem cell transplant, targeted therapy, and other therapies. Cancer can be treated by using one therapy or by using combination of therapies based on the stage, type of cancer, and other factors. Chemotherapy is the type of treatment, where the drugs are used to stop or slow the growth of cancer cells. Chemotherapy-induced thrombocytopenia is a serious complication in the chemotherapy-treated patients.

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic is expected to restrain the global chemotherapy-induced thrombocytopenia therapeutics market growth during the forecast period. The COVID-19 pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare sector has been impacted majorly due to the COVID-19 pandemic. The shutdown has disrupted the supply, distribution, and manufacture of medical supplies globally. Moreover, due to social distancing, the footfall in clinics and health institutions has fallen by over 70% during this pandemic, which has led to decrease in number of chemotherapy procedures, which has negatively impacted the market growth.
Furthermore, the coronavirus pandemic has hampered the development, clinical trials, production, and supply of drugs and other healthcare products and also have affected growth of the healthcare businesses of various companies across the globe. According to the Indian Journal of Medical Sciences, June 6, 2020, the COVID-19 pandemic has affected the conduction of clinical trials due to unavailability of trial site staff, restrictions for travelling, investigational product availability, and others. As a result, the impact of the COVID-19 pandemic is expected to limit growth of the market during the forecast period.

The global chemotherapy-induced thrombocytopenia therapeutics market is estimated to be valued at US$ 1,168.4 million in 2020 and is expected to exhibit a CAGR of 4.5% during the forecast period (2020-2027).


Get PDF Brochure Of This Research Report @ :
https://www.coherentmarketinsights.com/insight/request-pdf/4332

Increasing incidence of cancer is expected to drive growth of the global chemotherapy-induced thrombocytopenia therapeutics market during the forecast period.

Rising cancer cases is expected to increase the number of chemotherapy procedures and thereby expected to drive the chemotherapy-induced thrombocytopenia therapeutics market growth over the forecast period. For instance, according to the World Cancer Research Fund International’s report in 2018, the total number of cancer cases worldwide was around 17,036,901 in 2018.
Moreover, rising approvals from regulatory agencies such as the U.S. Food and Drug Administration (FDA) aiding in speedy approval by designating the orphan drug status to drugs targeted to benefit patients with rare disease is expected to boost the market growth. For instance, in December 2019, Dova Pharmaceuticals, Inc., a subsidiary of Swedish Orphan Biovitrum AB received the Orphan Drug Designation grant from the U.S. Food and Drug Administration (FDA) for avatrombopag, a treatment for chemotherapy-induced thrombocytopenia (CIT).


Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Restraints
Lack of approved drugs or therapeutics for the chemotherapy-induced thrombocytopenia is the major factor that is expected to hinder the market growth. Currently, Oprelvekin-recombinant interleukin-11 (IL-11) is the only thrombopoietic agent approved by the U.S. Food and Drug Administration for the treatment of chemotherapy-induced thrombocytopenia. It is indicated for adults with solid tumors and lymphomas associated with severe chemotherapy-induced thrombocytopenia.
Uncertainty of advancement of drug clinical trials and failure of therapeutics is the major factor that is expected to restrain the market growth over the forecast period. For instance, in October 2020, Swedish Orphan Biovitrum AB announced results of its phase III study of Avatrombopag (Doptelet), an oral thrombopoietin (TPO) receptor agonist, in solid tumor cancer patients with chemotherapy-induced thrombocytopenia (CIT). The study failed to meet the primary end point of avoiding platelet transfusions chemotherapy dose reductions by 15% or greater and also failed to show efficacy in chemotherapy-induced thrombocytopenia.

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Regional Analysis

On the basis of region, the global chemotherapy-induced thrombocytopenia therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to dominate the global chemotherapy-induced thrombocytopenia therapeutics market during the forecast period, owing to increasing cancer cases in the region. For instance, according to the Cancer Treatment & Survivorship Facts & Figures 2019-2021 Report published by the American Cancer Society, Inc., the estimated number of cancer cases in U.S. was around 16,920,370, as of 1st January 2019.


Request Sample Copy of Research Report @ :
https://www.coherentmarketinsights.com/insight/request-sample/4332

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - Competitive Landscape

Some of the key players operating in the global chemotherapy-induced thrombocytopenia therapeutics market include Amgen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc., Mission Pharmacal Company, Myelo Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., and Dova Pharmaceuticals, Inc. (Swedish Orphan Biovitrum)

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]